Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.


Player Avatar TMFTycoon (63.09) Submitted: 3/20/2014 3:53:53 PM : Outperform Start Price: $328.69 REGN Score: +20.11

Things are looking good for Eylea, one of Regeneron's drugs, and it is scheduled for further regulatory decisions and Phase III testing later this year.

Featured Broker Partners